[Source]
On October 31, 2013 CordenPharma acquired Ancora Pharmaceuticals, located in Woburn, MA, USA. Ancora’s unique carbohydrate synthesis technology platform and chemistry research facilities perfectly complement CordenPharma’s capabilities in the manufacture and supply of high-quality complex synthetic molecules.
As a result of the acquisition, Ancora’s extensive know-how and historical expertise in carbohydrate synthesis will be merged with CordenPharma’s process development, scale-up and cGMP manufacturing capabilities.
This acquisition is a key step in CordenPharma’s strategy to become the leading global supplier of synthetic carbohydrates for all applications, including glycoconjugate vaccine antigens, immunomodulatory therapeutics, tissue targeting/drug delivery motifs, nutraceuticals, analytical reagents and standards, diagnostic reagents, and defined content for glycomics research.
Together, Ancora and CordenPharma are now equipped to provide carbohydrate synthesis and production needs from early stage discovery research through to commercial cGMP manufacturing at any scale. Both CordenPharma and Ancora will serve customers out of Ancora’s Woburn facility, with newly expanded capabilities for seamless transition to large scale cGMP manufacturing at CordenPharma’s facilities in the US and in Europe. While the Ancora brand will remain, inquiries will be evaluated and handled in coordination with CordenPharma in an effort to comprehensively cover all aspects from chemistry development to large-scale GMP manufacturing.
For more information on our expanded carbohydrates platform, please contact:
A. Stewart Campbell, Ph.D.
Head of Business Development & Product Management, Carbohydrates
Ancora, a Division of CordenPharma
1-B Gill St.
Woburn, MA 01801
Tel: (781) 305-3332 x 44
Fax: (781) 305-3350
[email protected]
www.ancorapharma.com